FindTrial
Sign In

Multi-central prospective randomized controlled trial of intravitreal injection of conbercept versus ranibizumab for retinopathy of prematurity

Multi-central prospective randomized controlled trial of intravitreal injection of conbercept versus ranibizumab for retinopathy of prematurity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038294
Enrollment
Unknown
Registered
2020-09-16
Start date
2017-05-01
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity

Interventions

Group 1:intravitreal injection of conbercept (IVC) by 0.3mg/0.03ml
Group 2:intravitreal injection of ranibizumab (IVR) by 0.3mg/0.03ml

Sponsors

Shenzhen Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children with aprop; 2. Children with ROP whose lesions were located in zone 1 or zone 2 of posterior pole; 3. The family members agreed to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The child has other eye diseases; 2. Patients who have received anti VEGF, retinal photocoagulation and other intervention therapy in the past.

Design outcomes

Primary

MeasureTime frame
Recurrent rate;—

Secondary

MeasureTime frame
Complications rate;—

Countries

China

Contacts

Public ContactZhang Guoming

Shenzhen Eye Hospital

13823509060@163.com+86 13823509060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026